Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

72408 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-01-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Second primary malignancy (SPM) significantly impacts the survival and prognosis of patients. This study endeavors to identify risk and prognostic factors associated with SPM after first primary kidney cancer and construct predictive nomograms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients

NCT02580929

Carcinoma, Hepatocellular

UNKNOWN NA

Radical Radiotherapy Versus Radical Surgery for UTUC

NCT06652009

Renal Pelvis Cancer

RECRUITING

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

NCT05600309

Colorectal Cancer

COMPLETED PHASE3

68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

NCT06613269

Clear Cell Renal Cell Carcinoma

RECRUITING PHASE2

Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC

NCT06598761

Ureter Cancer Renal Pelvic Carcinoma Advanced Urothelial Carcinoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In recent years, with the advancement of cancer treatment techniques and the prolonged survival of patients, the prevalence of Second primary malignancy (SPM) has been escalating, emerging as a significant health issue among cancer survivors. The goal of this study is to identify risk and prognostic factors associated with SPM after first primary kidney cancer and construct nomograms to provide clinical evidence. The main questions this study aims to answer are: (1) What are the risk factors associated with the prevalence of SPM after kidney cancer? (2) What are the prognostic factors associated with the overall survival (OS) of kidney cancer patients with SPM? (3) How to accurately predict the probability of developing SPM after kidney cancer and the OS of kidney cancer patients with SPM? In this retrospective population-based cohort study, Patients diagnosed with first primary kidney cancer between 2000 and 2020 were retrospectively enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. Researchers will concentrate on the risk and prognostic factors of SPM after kidney cancer, and develop nomograms to forecast the development and overall survival (OS) of SPM after kidney cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Kidney cancer patients with second primary malignancy (SPM)

Patients diagnosed with first primary kidney cancer and second primary malignancy between 2000 and 2020

Surgery, radiation therapy and chemotherapy

Intervention Type PROCEDURE

Surgery, radiation therapy and chemotherapy

Kidney cancer patients without SPM

Patients diagnosed with only first primary kidney cancer between 2000 and 2020

Surgery, radiation therapy and chemotherapy

Intervention Type PROCEDURE

Surgery, radiation therapy and chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surgery, radiation therapy and chemotherapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) Diagnosed age was between 18 and 80 years old
* (2) Diagnosed histologically confirmed as first primary kidney cancer
* (3) The staging of kidney cancer was early or localized advanced (T1/2/3N0M0)
* (4) Detailed survival data and follow-up information should be provided

Exclusion Criteria

* (1) Histological conformation for diagnosis was unavailable
* (2) The type of reporting source was "Death certificate only" or "Autopsy only"
* (3) Patients with other malignancies before the diagnosis of primary kidney cancer
* (4) The staging of kidney cancer was not early or localized advanced (T1/2/3N0M0)
* (5) Diagnosis interval between first primary malignancy (FPM) and second primary malignancy (SPM) was less than 6 months
* (6) The information was not complete

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No